nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-2019-4-22-27nnp-1204Research ArticleLECTURESЛЕКЦИЯPoststroke cognitive impairmentКогнитивные нарушения после инсультаПарфеновВ. А.ParfenovV. A.vladimirparfenov@mail.ruКафедра нервных болезней и нейрохирургии лечебного факультета ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский университет)» Минздрава РоссииРоссияDepartment of Nervous System Diseases and Neurosurgery, Faculty of General Medicine, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaRussian Federation2019071220191142227Copyright © Parfenov V.A., 20192019Парфенов В.А.Parfenov V.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/1204

Cognitive impairment (CI) is one of the leading causes of disability after stroke; CI is observed in more than half of patients and reaches a pronounced degree (of dementia) in every three to five patients. CI in poststroke patients is often caused not only by focal vascular lesions of the brain, but also by the presence of concomitant vascular and neurodegenerative diseases. The treatment and prevention of progressive CI are based on stroke prevention, non-drug and drug methods to improve cognitive functions. Blood pressure normalization during antihypertensive therapy is most effective in preventing the progression of CI in stroke patients. The use of Actovegin in patients with CI after stroke is discussed. The results of the author's own 5-year follow-up of 350 patients with stroke are presented.

Когнитивные нарушения (КН) представляют собой одну из ведущих причин инвалидности после перенесенного инсульта, они отмечаются более чем у половины больных и у каждого третьего–пятого достигают выраженной степени (деменции). У больных, перенесших инсульт, КН часто вызваны не только очаговым сосудистым поражением головного мозга, но и наличием сопутствующих сосудистых и нейродегенеративных поражений. Лечение и профилактика прогрессирования КН основаны на профилактике инсульта, нелекарственных и лекарственных методах улучшения когнитивных функций. Нормализация артериального давления на фоне антигипертензивной терапии является наиболее эффективным направлением предупреждения прогрессирования КН у больных, перенесших инсульт. Обсуждается применение Актовегина у больных с КН поcле перенесенного инсульта. Представлены результаты собственного 5-летнего наблюдения 350 больных, перенесших инсульт.

постинсультные когнитивные нарушенияпрофилактика повторного инсультаАктовегинpost-stroke cognitive impairmentprevention of recurrent strokeActoveginПубликация статьи поддержана ООО «Такеда Фармасьютикалс».ReferencesГусев ЕИ, Боголепова АН. Когнитивные нарушения при цереброваскулярных заболеваниях. Москва: МЕДпресс-информ; 2013. 180 с.Gusev EI, Bogolepova AN. Kognitivnye narusheniya pri tserebrovaskulyarnykh zabolevaniyakh [Cognitive impairment in cerebrovascular diseases]. Moscow: MEDpress-inform; 2013. 180 p. (In Russ.)Парфенов ВА, Захаров ВВ, Преображенская ИС. Когнитивные расстройства. Москва: Ремедиум; 2014. 224 с.Parfenov VA, Zakharov VV, Preobrazhenskaya IS. Kognitivnye rasstroistva [Cognitive disorders]. Moscow: Remedium; 2014. 224 p. (In Russ.)Gaynor E, Rohde D, Large M, et al. Cognitive Impairment, Vulnerability, and Mortality Post Ischemic Stroke: A Five-Year Follow-Up of the Action on Secondary Prevention Interventions and Rehabilitation in Stroke (ASPIRE-S) Cohort. J Stroke Cerebrovasc Dis. 2018 Sep;27(9):2466-73. doi: 10.1016/j.jstrokecerebrovasdis.2018.05.002Gaynor E, Rohde D, Large M, et al. Cognitive Impairment, Vulnerability, and Mortality Post Ischemic Stroke: A Five-Year Follow-Up of the Action on Secondary Prevention Interventions and Rehabilitation in Stroke (ASPIRE-S) Cohort. J Stroke Cerebrovasc Dis. 2018 Sep;27(9):2466-73. doi: 10.1016/j.jstrokecerebrovasdis.2018.05.002Gorelick PB, Scuteri A, Black SE, et al. Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2011;42:2672-713. doi: 10.1161/STR.0b013e3182299496Gorelick PB, Scuteri A, Black SE, et al. Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2011;42:2672-713. doi: 10.1161/STR.0b013e3182299496Sun JH, Tan L, Yu JT. Post-stroke cognitive impairment: epidemiology, mechanisms and management. Ann Transl Med. 2014;2(8):80-96.Sun JH, Tan L, Yu JT. Post-stroke cognitive impairment: epidemiology, mechanisms and management. Ann Transl Med. 2014;2(8):80-96.Rist PM, Chalmers J, Arima H, et al. Baseline cognitive function, recurrent stroke, and risk of dementia in patients with stroke. Stroke. 2013;44:1790-5. doi: 10.1161/STROKEAHA.111.680728Rist PM, Chalmers J, Arima H, et al. Baseline cognitive function, recurrent stroke, and risk of dementia in patients with stroke. Stroke. 2013;44:1790-5. doi: 10.1161/STROKEAHA.111.680728Gutierrez Perez C, Savborg M, Pahlman U, et al. High frequency of cognitive dysfunction before stroke among older people. Int J Geriatr Psychiatry. 2011;26:622-9. doi:10.1002/gps.2573Gutierrez Perez C, Savborg M, Pahlman U, et al. High frequency of cognitive dysfunction before stroke among older people. Int J Geriatr Psychiatry. 2011;26:622-9. doi:10.1002/gps.2573Douiri A, Rudd AG, Wolfe CD. Prevalence of poststroke cognitive impairment: South London Stroke Register 1995–2010. Stroke. 2013;44:138-45. doi: 10.1161/STROKEAHA.112.670844Douiri A, Rudd AG, Wolfe CD. Prevalence of poststroke cognitive impairment: South London Stroke Register 1995–2010. Stroke. 2013;44:138-45. doi: 10.1161/STROKEAHA.112.670844Jacquin A, Binquet C, Rouaud O, et al. Post-stroke cognitive impairment: high prevalence and determining factors in a cohort of mild stroke. J Alzheimers Dis. 2014;40:1029-38. doi: 10.3233/JAD-131580Jacquin A, Binquet C, Rouaud O, et al. Post-stroke cognitive impairment: high prevalence and determining factors in a cohort of mild stroke. J Alzheimers Dis. 2014;40:1029-38. doi: 10.3233/JAD-131580Jokinen H, Melkas S, Ylikoski R, et al. Post-stroke cognitive impairment is common even after successful clinical recovery. Eur J Neurol. 2015; 22(9):1288-94. doi: 10.1111/ene.12743Jokinen H, Melkas S, Ylikoski R, et al. Post-stroke cognitive impairment is common even after successful clinical recovery. Eur J Neurol. 2015; 22(9):1288-94. doi: 10.1111/ene.12743O’Brien J, Ames D, Gustafson L, et al, eds. Cerebrovascular disease, cognitive impairment and dementia. Cerebrovascular disease and dementia. 2nd ed. London; N.Y.: Martin Dunitz; 2004.O’Brien J, Ames D, Gustafson L, et al, eds. Cerebrovascular disease, cognitive impairment and dementia. Cerebrovascular disease and dementia. 2nd ed. London; N.Y.: Martin Dunitz; 2004.Benisty S, Gouw AA, Porcher R, et al. Location of lacunar infarcts correlates with cognition in a sample of non-disabled subjects with age-related white-matter changes: the LADIS study. J Neurol Neurosurg Psychiatry. 2009;80: 478-83. doi: 10.1136/jnnp.2008.160440Benisty S, Gouw AA, Porcher R, et al. Location of lacunar infarcts correlates with cognition in a sample of non-disabled subjects with age-related white-matter changes: the LADIS study. J Neurol Neurosurg Psychiatry. 2009;80: 478-83. doi: 10.1136/jnnp.2008.160440Sachdev P, Kalaria R, O’Brien J, et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord. 2014;28(3):206-18. doi: 10.1097/WAD.0000000000000034Sachdev P, Kalaria R, O’Brien J, et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord. 2014;28(3):206-18. doi: 10.1097/WAD.0000000000000034Jacova C, Pearce LA, Costello R, et al. Cognitive impairment in lacunar strokes: the SPS3 trial. Ann Neurol. 2012;72:351-62. doi: 10.1002/ana.23733Jacova C, Pearce LA, Costello R, et al. Cognitive impairment in lacunar strokes: the SPS3 trial. Ann Neurol. 2012;72:351-62. doi: 10.1002/ana.23733Barker WW, Luis CA, Kashuba A. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord. 2002;16(4): 203-12. doi: 10.1097/00002093-200210000-00001Barker WW, Luis CA, Kashuba A. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord. 2002;16(4): 203-12. doi: 10.1097/00002093-200210000-00001Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with prestroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol. 2009;8: 1006-18. doi: 10.1016/S1474-4422(09)70236-4Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with prestroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol. 2009;8: 1006-18. doi: 10.1016/S1474-4422(09)70236-4Altieri M, Di Piero V, Pasquini M, et al. Delayed poststroke dementia: a 4-year followup study. Neurology. 2004 Jun 22;62(12):2193-7. doi: 10.1212/01.WNL.0000130501.79012.1AAltieri M, Di Piero V, Pasquini M, et al. Delayed poststroke dementia: a 4-year followup study. Neurology. 2004 Jun 22;62(12):2193-7. doi: 10.1212/01.WNL.0000130501.79012.1AGemmell E, Tam E, Allan L, et al. Neuron volumes in hippocampal subfields in delayed poststroke and aging-related dementias. J Neuropathol Exp Neurol. 2014;73:305-11. doi: 10.1097/NEN.0000000000000054Gemmell E, Tam E, Allan L, et al. Neuron volumes in hippocampal subfields in delayed poststroke and aging-related dementias. J Neuropathol Exp Neurol. 2014;73:305-11. doi: 10.1097/NEN.0000000000000054Sahathevan R, Brodtmann A, Donnan GA. Dementia, stroke, and vascular risk factors; a review. Int J Stroke. 2012;7:61-73. doi: 10.1111/j.1747-4949.2011.00731.xSahathevan R, Brodtmann A, Donnan GA. Dementia, stroke, and vascular risk factors; a review. Int J Stroke. 2012;7:61-73. doi: 10.1111/j.1747-4949.2011.00731.xMohd Zulkifly MF, Ghazali SE, Che Din N, et al. The influence of demographic, clinical, psychological and functional determinants on post-stroke cognitive impairment at day care stroke center, Malaysia. Malays J Med Sci. 2016;23(2):53-64.Mohd Zulkifly MF, Ghazali SE, Che Din N, et al. The influence of demographic, clinical, psychological and functional determinants on post-stroke cognitive impairment at day care stroke center, Malaysia. Malays J Med Sci. 2016;23(2):53-64.Arba F, Quinn T, Hankey GJ, et al. Determinants of post-stroke cognitive impairment: analysis from VISTA. Acta Neurol Scand. 2017;135(6):603-7. doi: 10.1111/ane.12637Arba F, Quinn T, Hankey GJ, et al. Determinants of post-stroke cognitive impairment: analysis from VISTA. Acta Neurol Scand. 2017;135(6):603-7. doi: 10.1111/ane.12637Sibolt G, Curtze S, Melkas S, et al. Poststroke dementia is associated with recurrent ischaemic stroke. J Neurol Neurosurg Psychiatry. 2013;84:722-6. doi: 10.1136/jnnp-2012-304084Sibolt G, Curtze S, Melkas S, et al. Poststroke dementia is associated with recurrent ischaemic stroke. J Neurol Neurosurg Psychiatry. 2013;84:722-6. doi: 10.1136/jnnp-2012-304084Jellinger KA. The enigma of mixed dementia. Alzheimers Dement. 2007;3:40-53. doi: 10.1016/j.jalz.2006.09.002Jellinger KA. The enigma of mixed dementia. Alzheimers Dement. 2007;3:40-53. doi: 10.1016/j.jalz.2006.09.002Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular Dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43: 250-60. doi: 10.1212/WNL.43.2.250Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular Dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43: 250-60. doi: 10.1212/WNL.43.2.250Oberlin LE., Waiwood AM, Cumming TB, et al. Effects of physical activity on post-stroke cognitive function: a meta-analysis of randomized controlled trials. Stroke. 2017 Nov;48(11): 3093-100. doi: 10.1161/STROKEAHA.117.017319Oberlin LE., Waiwood AM, Cumming TB, et al. Effects of physical activity on post-stroke cognitive function: a meta-analysis of randomized controlled trials. Stroke. 2017 Nov;48(11): 3093-100. doi: 10.1161/STROKEAHA.117.017319Ankolekar S, Geeganage C, Anderton P, et al. Clinical trials for preventing post stroke cognitive impairment. J Neurol Sci. 2010;299 (1-2):168-74. doi: 10.1016/j.jns.2010.08.052Ankolekar S, Geeganage C, Anderton P, et al. Clinical trials for preventing post stroke cognitive impairment. J Neurol Sci. 2010;299 (1-2):168-74. doi: 10.1016/j.jns.2010.08.052Gorelick PB. Blood Pressure and the Prevention of Cognitive Impairment. JAMA Neurol. 2014;71:1211-3. doi: 10.1001/jamaneurol.2014.2014Gorelick PB. Blood Pressure and the Prevention of Cognitive Impairment. JAMA Neurol. 2014;71:1211-3. doi: 10.1001/jamaneurol.2014.2014Ihle-Hansen H, Thommessen B, Fagerland MW, et al. Blood pressure control to prevent decline in cognition after stroke. Vasc Health Risk Manag. 2015;11:311-6. doi: 10.2147/VHRM.S82839Ihle-Hansen H, Thommessen B, Fagerland MW, et al. Blood pressure control to prevent decline in cognition after stroke. Vasc Health Risk Manag. 2015;11:311-6. doi: 10.2147/VHRM.S82839European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack. Cerebrovasc Dis. 2008;25:457-507. doi: 10.1159/000131083European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack. Cerebrovasc Dis. 2008;25:457-507. doi: 10.1159/000131083Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49(3):e46-e110. doi: 10.1161/STR.0000000000000158Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49(3):e46-e110. doi: 10.1161/STR.0000000000000158Вербицкая СВ, Парфенов ВА, Решетников ВА и др. Постинсультные когнитивные расстройства (результаты 5-летнего наблюдения). Неврология, нейропсихиатрия и психосоматика. 2018;10(1):37-42 doi: 10.14412/2074-2711-2018-1-37-42Verbitskaya SV, Parfenov VA, Reshetnikov VA, et al. Post-stroke cognitive impairment (results of a 5-year follow-up). Nevrologiya, Neiropsikhiatriya, Psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2018;10(1):37-42 (In Russ.) doi: 10.14412/2074-2711-2018-1-37-42Mahon S, Parmar P, Barker-Collo S, et al. Determinants, prevalence, and trajectory of long-term post-stroke cognitive impairment. Results from a 4-year follow-up of the ARCOS-IV study. Neuroepidemiology. 2017;49(3-4):129-34. doi: 10.1159/000484606Mahon S, Parmar P, Barker-Collo S, et al. Determinants, prevalence, and trajectory of long-term post-stroke cognitive impairment. Results from a 4-year follow-up of the ARCOS-IV study. Neuroepidemiology. 2017;49(3-4):129-34. doi: 10.1159/000484606Solomon A, Mangialasche F, Richard E, et al. Advances in the prevention of Alzheimer’s disease and dementia. J Intern Med. 2014;275(3): 229-50. doi: 10.1111/joim.12178Solomon A, Mangialasche F, Richard E, et al. Advances in the prevention of Alzheimer’s disease and dementia. J Intern Med. 2014;275(3): 229-50. doi: 10.1111/joim.12178Levi Marpillat N, Macquin-Mavier I, Tropeano AI, et al. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. J Hypertens. 2013; 31(6):1073-82. doi: 10.1097/HJH.0b013e3283603f53Levi Marpillat N, Macquin-Mavier I, Tropeano AI, et al. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. J Hypertens. 2013; 31(6):1073-82. doi: 10.1097/HJH.0b013e3283603f53Machicao F, Muresanu DF, Hundsberger H, et al. Pleiotropic neuroprotective and metabolic effects of Actovegin's mode of action. J Neurol Sci. 2012;322(1):222-7. doi: 10.1016/j.jns.2012.07.069Machicao F, Muresanu DF, Hundsberger H, et al. Pleiotropic neuroprotective and metabolic effects of Actovegin's mode of action. J Neurol Sci. 2012;322(1):222-7. doi: 10.1016/j.jns.2012.07.069Herrmann WM, Bohn-Olszewsky WJ, Kuntz G. Actovegin infusion treatment in patients with primarily degenerative dementia of the Alzheimer type and multi-infarct dementia. Zeitschrift fü r Geriatrie. 1992;5:46-55.Herrmann WM, Bohn-Olszewsky WJ, Kuntz G. Actovegin infusion treatment in patients with primarily degenerative dementia of the Alzheimer type and multi-infarct dementia. Zeitschrift fü r Geriatrie. 1992;5:46-55.Kanowski S, Kinzler E, Lehmann E, Schweizer A, Kuntz C. Confirmed Clinical Efficacy of Actoveginmin Elderly Patients with Organic Brain Syndrome. Pharmacopsychiat. 1995;28:125-33. doi: 10.1055/s-2007-979604Kanowski S, Kinzler E, Lehmann E, Schweizer A, Kuntz C. Confirmed Clinical Efficacy of Actoveginmin Elderly Patients with Organic Brain Syndrome. Pharmacopsychiat. 1995;28:125-33. doi: 10.1055/s-2007-979604Guekht A, Skoog I, Edmundson S, Zakharov V, Korczyn A. ARTEMIDA trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment. Stroke. 2017;48:1262-70. doi: 10.1161/STROKEAHA.116.014321Guekht A, Skoog I, Edmundson S, Zakharov V, Korczyn A. ARTEMIDA trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment. Stroke. 2017;48:1262-70. doi: 10.1161/STROKEAHA.116.014321

The authors declare that there are no conflicts of interest present.